×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Tags: tb | tuberculosis | treatment | priftin

Help for Latent TB

Tuesday, 02 December 2014 08:07 AM

Sanofi said on Tuesday the U.S. Food and Drug Administration had approved its Priftin (rifapentine) drug in combination with isoniazid (INH) for a new indication, in the treatment of latent tuberculosis infection.

The oral drug, first approved in the United States in 1998 to treat active pulmonary TB, can now be prescribed to patients over two years old and at high risk of developing the disease.
Sanofi said it was exploring the drug's potential for regulatory approval in other countries.
 
According to the World Health Organization, 9 million people fell sick with TB in 2013 and 1.5 million died from the disease.

© 2021 Thomson/Reuters. All rights reserved.


FDA-Approved-Drugs
Sanofi said on Tuesday the U.S. Food and Drug Administration had approved its Priftin (rifapentine) drug in combination with isoniazid (INH) for a new indication, in the treatment of latent tuberculosis infection.The oral drug, first approved in the United States in 1998 to...
tb, tuberculosis, treatment, priftin
102
2014-07-02
Tuesday, 02 December 2014 08:07 AM
Newsmax Media, Inc.
Join the Newsmax Community
Register To Comment Login To Comment
Please review Community Guidelines before posting a comment.
 
Find Your Condition
TOP

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved
NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved